Feb. 13, 2025 /PRNewswire/ -- GenomOncology, a precision medicine software company, and Pillar Biosciences, a leader in Decision Medicineâ„¢, today announced a co-marketing partnership aimed at ...
today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results